BETA
Your AI-Trained Oncology Knowledge Connection!
Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets
The median CNS PFS with Dato-DXd was 5.0 months vs 3.0 months with docetaxel in patients with NSCLC who have brain metastases.
Concurrent Durvalumab Plus Chemo/RT Does Not Improve Efficacy in Stage III NSCLC
For patients with unresectable stage III NSCLC, concurrent durvalumab with chemotherapy/radiation did not show an efficacy improvement.
Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC
The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.
Zidesamtinib Exhibits Durable Activity in Pretreated ROS1+ Advanced NSCLC
Zidesamtinib was well tolerated in patients who received prior ROS1 TKI therapy with advanced NSCLC, and dose discontinuation/reduction rates were low.
Ivonescimab/Chemo After TKI Progression Improves PFS in EGFR-Mutated NSCLC
Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.
Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions
Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population.
Perioperative Pembrolizumab Combo Improves Responses in NSCLC Subgroups
Subgroup data from KEYNOTE-671 support the use of perioperative pembrolizumab in stage II or III non–small cell lung cancer of any clinical nodal status.
Osimertinib Combo Exhibits OS Improvement in EGFR-Mutated Advanced NSCLC
AE-related discontinuations of osimertinib were low, and no new treatment-related deaths were reported with the combination in EGFR-mutant NSCLC.
The Clinical Implications of Having a “Cure” in Multiple Myeloma
Sundar Jagannath, MBBS, said that when a cure is defined for patients with multiple myeloma, specific patients may be able to stop therapy without a risk of relapsing.
Cardiovascular Considerations in Breast Cancer Treatment and Survivorship
Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.
After 5 Years of No CR MRD with Cilta-Cel, No Maintenance Required
Results from the phase 1b/2 CARTITUDE-1 trial showed that after patients receiving cilta-cel were disease-free for 5 years, they did not need maintenance therapy.
Trastuzumab Pamirtecan Improves PFS in HER2+ Metastatic Breast Cancer
Trastuzumab pamirtecan’s developers plan to discuss next steps regarding a submission of a biologics license application for this breast cancer population.
Reducing Animal Proteins, Increasing Fiber May Benefit Patients With Cancer
Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
Factoring Patient Goals Into TKI Selection for CML Treatment
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
New Blood Test Algorithm Shows Sensitivity, Specificity in CRC Screening
The performance of the latest Shield algorithm underwent validation in an expanded cohort of individuals enrolled on the ECLIPSE study.
Smaller, More Frequent Meals May Mitigate Nausea in Cancer Care
Bland foods, such as crackers and chicken noodle soup, as well as fluids with electrolytes, may help stave off treatment-related nausea.
Outlining Historical Standards for Treatment in Newly Diagnosed CML
The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.
Mosunetuzumab Exhibits Meaningful Responses in Untreated MZL
The safety and cytokine release syndrome profiles of mosunetuzumab were manageable in patients with previously untreated marginal zone lymphoma.
Benmelstobart Combo Elicits PFS Advantage in Untreated Advanced ccRCC
Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.
Obtaining and Defining a Cure in Multiple Myeloma
The approach to treating patients with multiple myeloma will change for physicians, pharmaceutical companies, and even patients themselves.
Subcutaneous Daratumumab Improves PFS in Smoldering Multiple Myeloma
Data from the AQUILA trial support early intervention with fixed-duration subcutaneous daratumumab for those with high-risk smoldering multiple myeloma.
Optimizing Clinical Decision Strategies for Ruxolitinib in Myelofibrosis
Predictors of response have a significant effect on clinical decision-making because they may help oncologists select the best treatment for specific patients.
Nutritional Supplementation May Interfere With Cancer Treatment
According to Denise B. Reynolds, RD, patients eating well should not be experiencing nutritional deficiencies during cancer treatment.
GLP-1 Agonists Show Therapeutic Benefits in Polycythemia Vera Population
Data from a propensity-matched analysis showed that GLP-1 receptor agonists conferred benefits even among patients with type 2 diabetes.
Analyzing Predictive Biomarkers for Ruxolitinib Treatment in Myelofibrosis
Delaying treatment with ruxolitinib by more than a year leads to decreased response rates and overall survival in patients with myelofibrosis.
Venetoclax/Azacitidine Yields No OS Improvement in Intermediate/High Risk MDS
The modified overall response rate was higher with venetoclax/azacitidine vs placebo/azacitidine in patients with intermediate/high risk MDS.
Tisotumab Vedotin Earns Hong Kong Approval in Recurrent Cervical Cancer
Patients with recurrent or metastatic cervical cancer in Hong Kong are now eligible to receive treatment with tisotumab vedotin.
Navigating Nutritional Challenges in Cancer Survivorship and Care
Referrals to dietitians may help in the management of TEAEs affecting taste and smell, as well as fatigue in patients undergoing cancer treatment.
Health Canada Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
Results from the phase 3 MIRASOL trial led to the approval of mirvetuximab soravtansine for patients with FRα+ ovarian cancer.
FDA Grants Breakthrough Therapy Designation to Zongertinib Tablets in NSCLC
Results from the Beamion-LUNG 1 trial showed an ORR of 75% for patients with HER2+ NSCLC treated with zongertinib.
